日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

美洛氟芬治疗复发/难治性多发性骨髓瘤患者的疗效

Hossain, Shahrier; Mo, Clifton; Patches, Sarah; Leblebjian, Houry; Goodrich, Kathryn; Regan, Eileen; O'Neill, Kathleen; Noonan, Kim; Richardson, Paul G; Laubach, Jacob

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

CAPOX BETR 的临床结果和 ctDNA 相关性:一项卡培他滨、奥沙利铂、贝伐珠单抗、曲妥珠单抗治疗既往未接受治疗的晚期 HER2+ 胃食管腺癌的 II 期试验

Singh, Harshabad; Lowder, Kristen E; Kapner, Kevin; Kelly, Ronan J; Zheng, Hui; McCleary, Nadine Jackson; Abrams, Thomas A; Chan, Jennifer A; Regan, Eileen M; Klempner, Samuel J; Hannigan, Alison M; Remland, Joshua; Brais, Lauren K; Andrews, Elizabeth; Yurgelun, Matthew; Cleary, James M; Rubinson, Douglas A; Ritterhouse, Lauren L; Maron, Garrett; Aguirre, Andrew J; Meyerhardt, Jeffrey A; Gardecki, Emma; Lennerz, Jochen K; Wolpin, Brian M; Enzinger, Peter C

Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy

卡非佐米诱导的血栓性微血管病多发性骨髓瘤患者的替代补体途径突变

Moscvin, Maria; Liacos, Christine Ivy; Chen, Tianzeng; Theodorakakou, Foteini; Fotiou, Despina; Hossain, Shahrier; Rowell, Sean; Leblebjian, Houry; Regan, Eileen; Czarnecki, Peter; Bagnoli, Filippo; Bolli, Niccolo'; Richardson, Paul; Rennke, Helmut G; Dimopoulos, Meletios A; Kastritis, Efstathios; Bianchi, Giada

The Oxford Agoraphobic Avoidance Scale

牛津广场恐惧症回避量表

Lambe, Sinead; Bird, Jessica C; Loe, Bao Sheng; Rosebrock, Laina; Kabir, Thomas; Petit, Ariane; Mulhall, Sophie; Jenner, Lucy; Aynsworth, Charlotte; Murphy, Elizabeth; Jones, Julia; Powling, Rosie; Chapman, Kate; Dudley, Robert; Morrison, Anthony; Regan, Eileen O; Yu, Ly-Mee; Clark, David; Waite, Felicity; Freeman, Daniel

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

索拉非尼联合改良FOLFOX方案治疗晚期肝细胞癌患者的II期生物标志物研究

Goyal Lipika, Zheng Hui, Abrams Thomas A, Miksad Rebecca, Bullock Andrea J, Allen Jill N, Yurgelun Matthew B, Clark Jeffrey W, Kambadakone Avinash, Muzikansky Alona, Knowles Michelle, Galway Aralee, Afflitto Anthony J, Dinicola Caroline F, Regan Eileen, Hato Tai, Mamessier Emilie, Shigeta Kohei, Jain Rakesh K, Duda Dan G, Zhu Andrew X

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

卡博替尼治疗晚期胆管癌患者的 2 期临床试验及生物标志物研究

Goyal Lipika, Zheng Hui, Yurgelun Matthew B, Abrams Thomas A, Allen Jill N, Cleary James M, Knowles Michelle, Regan Eileen, Reardon Amanda, Khachatryan Anna, Jain Rakesh K, Nardi Valentina, Borger Darrell R, Duda Dan G, Zhu Andrew X

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.

西地尼布单药治疗晚期肝细胞癌的疗效、安全性、药代动力学和生物标志物:一项 II 期研究

Zhu Andrew X, Ancukiewicz Marek, Supko Jeffrey G, Sahani Dushyant V, Blaszkowsky Lawrence S, Meyerhardt Jeffrey A, Abrams Thomas A, McCleary Nadine Jackson, Bhargava Pankaj, Muzikansky Alona, Sheehan Susan, Regan Eileen, Vasudev Eamala, Knowles Michelle, Fuchs Charles S, Ryan David P, Jain Rakesh K, Duda Dan G

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

一项前瞻性 I/II 期研究,评估依维莫司和替莫唑胺治疗晚期胰腺神经内分泌肿瘤患者的疗效

Chan, Jennifer A; Blaszkowsky, Lawrence; Stuart, Keith; Zhu, Andrew X; Allen, Jill; Wadlow, Raymond; Ryan, David P; Meyerhardt, Jeffrey; Gonzalez, Marielle; Regan, Eileen; Zheng, Hui; Kulke, Matthew H

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer

一项针对难治性转移性结直肠癌患者的替沃扎尼(AV-951)联合依维莫司(RAD001)的多中心II期研究

Wolpin, Brian M; Ng, Kimmie; Zhu, Andrew X; Abrams, Thomas; Enzinger, Peter C; McCleary, Nadine J; Schrag, Deborah; Kwak, Eunice L; Allen, Jill N; Bhargava, Pankaj; Chan, Jennifer A; Goessling, Wolfram; Blaszkowsky, Lawrence S; Supko, Jeffrey G; Elliot, Meaghan; Sato, Kaori; Regan, Eileen; Meyerhardt, Jeffrey A; Fuchs, Charles S

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

索拉非尼联合依维莫司治疗晚期神经内分泌肿瘤患者的I期研究(RAD001)

Chan, Jennifer A; Mayer, Robert J; Jackson, Nadine; Malinowski, Paige; Regan, Eileen; Kulke, Matthew H